Endocrine Disruptors and Life STILe in Breast Cancer Development
NCT05748353 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 275
Last updated 2024-04-12
Summary
The aim of the study is to evaluate the role of lifestyle and environmental factors ( environmental contaminants such as Cd) on the penetrance of BRCA1/2 genes in BRCAm patients with Breast cancer and/or Ovarian cancer and in BRCAm healthy women without cancer diagnosis
Conditions
- Breast Cancer
- BRCA1 Mutation
- BRCA2 Mutation
- Ovarian Cancer
- Life Style
- Cadmium Exposure
Sponsors & Collaborators
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
lead OTHER
Principal Investigators
-
Alessandra Fabi · Medicina di precisione in senologia, policliclinico A. Gemelli - IRCCS
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-01-01
- Primary Completion
- 2024-06-15
- Completion
- 2024-07-15
Countries
- Italy
Study Locations
More Related Trials
-
Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers
NCT06800612 ·Status: RECRUITING
-
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
NCT00003095 ·Status: COMPLETED
-
PIK3CA in HER2+ BC and pCR Trial
NCT05750693 ·Status: UNKNOWN ·Phase: NA
-
Chemotherapy in Treating Women With Previously Treated Metastatic Breast Cancer
NCT00003236 ·Status: COMPLETED ·Phase: PHASE2
-
Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344
NCT00897026 ·Status: COMPLETED
-
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
NCT02315196 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
NCT03911973 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
NCT00353483 ·Status: RECRUITING
-
A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer
NCT06735742 ·Status: ACTIVE_NOT_RECRUITING
-
Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer
NCT00580333 ·Status: COMPLETED ·Phase: PHASE2
-
Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer
NCT01049425 ·Status: COMPLETED ·Phase: PHASE3
-
Physical Functional Side Effects of Taxane Chemotherapy for Breast Cancer
NCT01153282 ·Status: COMPLETED
-
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
NCT04660435 ·Status: RECRUITING
-
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
NCT05573893 ·Status: RECRUITING
-
Abraxane in Treatment of Metastatic Breast Cancer
NCT02555696 ·Status: COMPLETED
-
Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer
NCT01190345 ·Status: COMPLETED ·Phase: PHASE2
-
Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment
NCT01320111 ·Status: COMPLETED ·Phase: PHASE2
-
Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland
NCT01630226 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer
NCT00548899 ·Status: COMPLETED ·Phase: PHASE2
-
Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer
NCT03503799 ·Status: ACTIVE_NOT_RECRUITING
-
Real Time Molecular Analysis of Breast Cancer Receiving Neo-adjuvant Chemotherapy
NCT04504747 ·Status: RECRUITING
-
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
NCT03412643 ·Status: UNKNOWN ·Phase: PHASE2
-
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy
NCT02549430 ·Status: COMPLETED ·Phase: PHASE2
-
Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer
NCT00336791 ·Status: COMPLETED ·Phase: PHASE3
-
Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.
NCT05303129 ·Status: COMPLETED ·Phase: NA